Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T van Putten

Showing results (81-90 of 103) with videos related to

Pageof 11
Sort By:
Therapeutic Drug Monitoring|February 1, 1994
Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazineM Aravagiri, S R Marder, T Van Putten, et al.
The American Journal of Psychiatry|April 1, 1983
A comparison of patients who refuse and consent to neuroleptic treatmentS R Marder, A Mebane, C P Chien, et al.
Psychopharmacology Bulletin|January 1, 1991
Early prediction of relapse in schizophrenia: an application of receiver operating characteristic (ROC) methodsS R Marder, J Mintz, T Van Putten, et al.
Archives of General Psychiatry|November 1, 1984
Costs and benefits of two doses of fluphenazineS R Marder, T Van Putten, J Mintz, et al.
Hospital & Community Psychiatry|July 1, 1984
A study of medication refusal by involuntary psychiatric patientsS R Marder, E Swann, W J Winslade, et al.
Comprehensive Psychiatry|March 1, 1981
Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcomeP R May, T Van Putten, D J Jenden, et al.
The American Journal of Psychiatry|November 1, 1985
Psychotic patients' understanding of informed consentM Irwin, A Lovitz, S R Marder, et al.
Psychopharmacology Bulletin|January 1, 1989
Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazineS R Marder, T Van Putten, M Aravagiri, et al.
Therapeutic Drug Monitoring|May 1, 1990
Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassayM Aravagiri, S R Marder, T Van Putten, et al.
Psychopharmacology Bulletin|January 1, 1993
Systematic dosage reduction in treatment-resistant schizophrenic patientsT Van Putten, B D Marshall, R Liberman, et al.
Pageof 11

Showing results (81-90 of 103) with videos related to

Sort By:
Pageof 11
Therapeutic Drug Monitoring|February 1, 1994
Radioimmunoassay for 7-hydroxy metabolite of fluphenazine and its application to plasma level monitoring in schizophrenic patients treated long term with oral and depot fluphenazineM Aravagiri, S R Marder, T Van Putten, et al.
The American Journal of Psychiatry|April 1, 1983
A comparison of patients who refuse and consent to neuroleptic treatmentS R Marder, A Mebane, C P Chien, et al.
Psychopharmacology Bulletin|January 1, 1991
Early prediction of relapse in schizophrenia: an application of receiver operating characteristic (ROC) methodsS R Marder, J Mintz, T Van Putten, et al.
Archives of General Psychiatry|November 1, 1984
Costs and benefits of two doses of fluphenazineS R Marder, T Van Putten, J Mintz, et al.
Hospital & Community Psychiatry|July 1, 1984
A study of medication refusal by involuntary psychiatric patientsS R Marder, E Swann, W J Winslade, et al.
Comprehensive Psychiatry|March 1, 1981
Prognosis in schizophrenia: individual differences in psychological response to a test dose of antipsychotic drug and their relationship to blood and saliva levels and treatment outcomeP R May, T Van Putten, D J Jenden, et al.
The American Journal of Psychiatry|November 1, 1985
Psychotic patients' understanding of informed consentM Irwin, A Lovitz, S R Marder, et al.
Psychopharmacology Bulletin|January 1, 1989
Plasma levels of parent drug and metabolites in patients receiving oral and depot fluphenazineS R Marder, T Van Putten, M Aravagiri, et al.
Therapeutic Drug Monitoring|May 1, 1990
Therapeutic monitoring of steady-state plasma levels of the N4'-oxide metabolite of fluphenazine in chronically treated schizophrenic patients determined by a specific and sensitive radioimmunoassayM Aravagiri, S R Marder, T Van Putten, et al.
Psychopharmacology Bulletin|January 1, 1993
Systematic dosage reduction in treatment-resistant schizophrenic patientsT Van Putten, B D Marshall, R Liberman, et al.
Pageof 11